Nutra Pharma Corp.
NPHC
$0.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 98.70K | 122.10K | 110.40K | 121.50K | 109.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.70K | 122.10K | 110.40K | 121.50K | 109.50K |
| Cost of Revenue | 34.10K | 46.50K | 42.10K | 34.90K | 38.80K |
| Gross Profit | 64.60K | 75.60K | 68.30K | 86.60K | 70.70K |
| SG&A Expenses | 420.70K | 366.20K | 418.20K | 265.50K | 255.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 454.80K | 412.70K | 460.20K | 300.40K | 294.20K |
| Operating Income | -356.10K | -290.50K | -349.80K | -178.90K | -184.80K |
| Income Before Tax | -523.50K | 369.60K | -1.40M | -230.90K | -260.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -523.50K | 369.60K | -1.40M | -230.90K | -260.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -523.50K | 369.60K | -1.40M | -230.90K | -260.70K |
| EBIT | -356.10K | -290.50K | -349.80K | -178.90K | -184.80K |
| EBITDA | -353.30K | -287.40K | -347.70K | -177.00K | -182.90K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 7.82B | 7.74B | 7.68B | 7.74B | 7.66B |
| Average Diluted Shares Outstanding | 7.82B | 37.73B | 7.68B | 7.74B | 7.66B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |